B. Riley Forecasts Cytokinetics’ Q2 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley upped their Q2 2025 earnings estimates for Cytokinetics in a research report issued to clients and investors on Wednesday, May 7th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($1.37) per share for the quarter, up from their prior […]

Leave a Reply

Your email address will not be published.

Previous post Equities Analysts Set Expectations for KBR Q2 Earnings
Next post Zacks Research Issues Pessimistic Estimate for IBKR Earnings